Do analysts rate NIOX or SPEC?

NIOX Group presently has a consensus target price of GBX 86, suggesting a potential upside of 34.22%. Given NIOX Group's stronger consensus rating and higher possible upside, equities analysts plainly believe NIOX Group is more favorable than INSPECS Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 INSPECS Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer NIOX or SPEC?

In the previous week, NIOX Group had 19 more articles in the media than INSPECS Group. MarketBeat recorded 20 mentions for NIOX Group and 1 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.75 beat NIOX Group's score of -0.11 indicating that INSPECS Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NIOX Group 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral INSPECS Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TSTL or SPEC more profitable?

Tristel has a net margin of 15.62% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.05% beat INSPECS Group's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.62% 23.05% 9.89% INSPECS Group -0.52% -1.19% 0.45%

Do analysts prefer SPEC or EKF?

EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 43.44%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than INSPECS Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INSPECS Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

INSPECS Group (SPEC) Competitors

GBX 85 -2.50 (-2.86%)

As of 04:26 AM Eastern

Compare

SPEC vs. NIOX, TSTL, EKF, CREO, and IUG

Should you buy INSPECS Group stock or one of its competitors? INSPECS Group's main competitors and comparable companies include NIOX Group (NIOX), Tristel (TSTL), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does INSPECS Group compare to NIOX Group?

NIOX Group (LON:NIOX) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, NIOX Group had 19 more articles in the media than INSPECS Group. MarketBeat recorded 20 mentions for NIOX Group and 1 mentions for INSPECS Group. INSPECS Group's average media sentiment score of 0.75 beat NIOX Group's score of -0.11 indicating that INSPECS Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NIOX Group	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
INSPECS Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NIOX Group has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, meaning that its stock price is 60% more volatile than the broader market.

NIOX Group presently has a consensus target price of GBX 86, suggesting a potential upside of 34.22%. Given NIOX Group's stronger consensus rating and higher possible upside, equities analysts plainly believe NIOX Group is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NIOX Group has a net margin of 14.74% compared to INSPECS Group's net margin of -0.52%. NIOX Group's return on equity of 10.01% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NIOX Group	14.74%	10.01%	3.95%
INSPECS Group	-0.52%	-1.19%	0.45%

7.6% of NIOX Group shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 5.1% of NIOX Group shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NIOX Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NIOX Group	£47.50M	5.47	£995.88M	£1.63	39.31
INSPECS Group	£193.23M	0.48	-£4.11M	-£5.34	N/A

Summary

NIOX Group beats INSPECS Group on 12 of the 16 factors compared between the two stocks.

How does INSPECS Group compare to Tristel?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Tristel has a net margin of 15.62% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.05% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.62%	23.05%	9.89%
INSPECS Group	-0.52%	-1.19%	0.45%

In the previous week, INSPECS Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for INSPECS Group and 0 mentions for Tristel. INSPECS Group's average media sentiment score of 0.75 beat Tristel's score of 0.00 indicating that INSPECS Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Tristel	Neutral
INSPECS Group	Positive

22.4% of Tristel shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, indicating that its share price is 60% more volatile than the broader market.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£51.12M	3.65	£6.54M	£16.57	23.42
INSPECS Group	£193.23M	0.48	-£4.11M	-£5.34	N/A

Summary

Tristel beats INSPECS Group on 9 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to EKF Diagnostics?

INSPECS Group (LON:SPEC) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, INSPECS Group had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for INSPECS Group and 0 mentions for EKF Diagnostics. INSPECS Group's average media sentiment score of 0.75 beat EKF Diagnostics' score of 0.00 indicating that INSPECS Group is being referred to more favorably in the media.

Company	Overall Sentiment
INSPECS Group	Positive
EKF Diagnostics	Neutral

EKF Diagnostics has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INSPECS Group	£193.23M	0.48	-£4.11M	-£5.34	N/A
EKF Diagnostics	£51.35M	2.03	£4.68M	£0.58	42.07

EKF Diagnostics has a consensus price target of GBX 35, indicating a potential upside of 43.44%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than INSPECS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INSPECS Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.7% of INSPECS Group shares are owned by institutional investors. Comparatively, 21.5% of EKF Diagnostics shares are owned by institutional investors. 19.6% of INSPECS Group shares are owned by company insiders. Comparatively, 40.2% of EKF Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

EKF Diagnostics has a net margin of 4.86% compared to INSPECS Group's net margin of -0.52%. EKF Diagnostics' return on equity of 3.58% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INSPECS Group	-0.52%	-1.19%	0.45%
EKF Diagnostics	4.86%	3.58%	5.27%

INSPECS Group has a beta of 1.603, meaning that its share price is 60% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.514, meaning that its share price is 49% less volatile than the broader market.

Summary

EKF Diagnostics beats INSPECS Group on 12 of the 16 factors compared between the two stocks.

How does INSPECS Group compare to Creo Medical Group?

Creo Medical Group (LON:CREO) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, indicating that its share price is 60% more volatile than the broader market.

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creo Medical Group	£7M	6.71	-£25.04M	-£5.00	N/A
INSPECS Group	£193.23M	0.48	-£4.11M	-£5.34	N/A

INSPECS Group has a net margin of -0.52% compared to Creo Medical Group's net margin of -268.57%. INSPECS Group's return on equity of -1.19% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creo Medical Group	-268.57%	-38.29%	-20.09%
INSPECS Group	-0.52%	-1.19%	0.45%

In the previous week, INSPECS Group had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for INSPECS Group and 0 mentions for Creo Medical Group. INSPECS Group's average media sentiment score of 0.75 beat Creo Medical Group's score of 0.00 indicating that INSPECS Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Creo Medical Group	Neutral
INSPECS Group	Positive

44.0% of Creo Medical Group shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 7.6% of Creo Medical Group shares are owned by company insiders. Comparatively, 19.6% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

INSPECS Group beats Creo Medical Group on 9 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, INSPECS Group had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for INSPECS Group and 0 mentions for Intelligent Ultrasound Group. INSPECS Group's average media sentiment score of 0.75 beat Intelligent Ultrasound Group's score of 0.00 indicating that INSPECS Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Intelligent Ultrasound Group	Neutral
INSPECS Group	Positive

Intelligent Ultrasound Group has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, meaning that its share price is 60% more volatile than the broader market.

75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. Comparatively, 0.7% of INSPECS Group shares are owned by institutional investors. 12.8% of Intelligent Ultrasound Group shares are owned by insiders. Comparatively, 19.6% of INSPECS Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

INSPECS Group has a net margin of -0.52% compared to Intelligent Ultrasound Group's net margin of -23.11%. INSPECS Group's return on equity of -1.19% beat Intelligent Ultrasound Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Ultrasound Group	-23.11%	-23.58%	-13.51%
INSPECS Group	-0.52%	-1.19%	0.45%

Intelligent Ultrasound Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Intelligent Ultrasound Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Ultrasound Group	£6.57M	0.00	-£2.27M	-£0.68	N/A
INSPECS Group	£193.23M	0.48	-£4.11M	-£5.34	N/A

Summary

INSPECS Group beats Intelligent Ultrasound Group on 9 of the 12 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPEC vs. The Competition

Export

Metric	INSPECS Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£92.80M	£6.02B	£7.84B	£2.83B
Dividend Yield	2.00%	1.69%	2.47%	5.12%
P/E Ratio	-15.92	38.97	34.14	23.40
Price / Sales	0.48	5.70	8.43	4.99
Price / Cash	1.63	24.25	22.22	20.23
Price / Book	0.85	4.30	4.42	2.46
Net Income	-£4.11M	£142.48M	£3.49B	£5.88B
7 Day Performance	-3.95%	-2.23%	-1.06%	-0.03%
1 Month Performance	-5.19%	-1.39%	-4.22%	-1.03%
1 Year Performance	25.18%	-1.59%	1.16%	7.04%

INSPECS Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPEC INSPECS Group	N/A	GBX 85 -2.9%	N/A	+22.3%	£92.80M	£193.23M	N/A	1,673	Gap Up
NIOX NIOX Group	1.7783 of 5 stars	GBX 68 -1.4%	GBX 86 +26.5%	-5.6%	£279.62M	£47.50M	41.72	92
TSTL Tristel	N/A	GBX 403.34 -0.4%	N/A	+6.6%	£194.70M	£51.12M	24.84	208
EKF EKF Diagnostics	N/A	GBX 23.80 +0.2%	GBX 35 +47.1%	-6.2%	£101.64M	£51.35M	41.03	356
CREO Creo Medical Group	N/A	GBX 11.40 +0.2%	GBX 40 +250.9%	-6.2%	£51.09M	£7M	N/A	279	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INSPECS Group (SPEC) Competitors

SPEC vs. NIOX, TSTL, EKF, CREO, and IUG

How does INSPECS Group compare to NIOX Group?

Summary

How does INSPECS Group compare to Tristel?

Summary

How does INSPECS Group compare to EKF Diagnostics?

Summary

How does INSPECS Group compare to Creo Medical Group?

Summary

How does INSPECS Group compare to Intelligent Ultrasound Group?

Summary

Media Sentiment Over Time

SPEC vs. The Competition

INSPECS Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INSPECS Group (SPEC) Competitors

SPEC vs. NIOX, TSTL, EKF, CREO, and IUG

How does INSPECS Group compare to NIOX Group?

Does the media prefer NIOX or SPEC?

Which has more volatility & risk, NIOX or SPEC?

Do analysts rate NIOX or SPEC?

Is NIOX or SPEC more profitable?

Do institutionals & insiders hold more shares of NIOX or SPEC?

Which has higher earnings and valuation, NIOX or SPEC?

Summary

How does INSPECS Group compare to Tristel?

Is TSTL or SPEC more profitable?

Does the media refer more to TSTL or SPEC?

Do insiders and institutionals believe in TSTL or SPEC?

Which has more volatility & risk, TSTL or SPEC?

Which has better valuation & earnings, TSTL or SPEC?

Summary

How does INSPECS Group compare to EKF Diagnostics?

Does the media favor SPEC or EKF?

Which has higher earnings & valuation, SPEC or EKF?

Do analysts prefer SPEC or EKF?

Do institutionals & insiders hold more shares of SPEC or EKF?

Is SPEC or EKF more profitable?

Which has more volatility and risk, SPEC or EKF?

Summary

How does INSPECS Group compare to Creo Medical Group?

Which has more volatility and risk, CREO or SPEC?

Which has stronger valuation and earnings, CREO or SPEC?

Is CREO or SPEC more profitable?

Does the media refer more to CREO or SPEC?

Do insiders and institutionals believe in CREO or SPEC?

Summary

How does INSPECS Group compare to Intelligent Ultrasound Group?

Does the media favor IUG or SPEC?

Which has more risk & volatility, IUG or SPEC?

Do institutionals & insiders believe in IUG or SPEC?

Is IUG or SPEC more profitable?

Which has higher earnings & valuation, IUG or SPEC?

Summary

Media Sentiment Over Time

SPEC vs. The Competition

INSPECS Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools